Once-weekly insulin icodec with dosing guide app showed superior HbA1c reduction versus once-daily insulin in phase 3a trial

The ONWARDS 5 trial randomly assigned 1,085 insulin-naïve adults with type 2 diabetes in seven countries to either weekly icodec titrated with a dosing guide app (icodec with app) or once-daily basal insulin (OD analogs) dosed per standard practice.

The two groups were compared for effectiveness and safety. The authors found that participants using icodec with app experienced a greater HbA1c reduction, treatment satisfaction, and adherence compared to participants using the OD insulin. According to the authors, the use of icodec with a dosing guide app could conceivably address several challenges seen in everyday practice, including inadequate dose titration and nonadherence to prescribed treatment regimens for patients with diabetes.

Reference:

Harpreet S. Bajaj, Jens Aberle, Melanie Davies, Anders Meller Donatsky, Marie Frederiksen, Dilek G. Yavuz, Amoolya Gowda, Ildiko Lingvay, and Bruce Bode, Once-Weekly Insulin Icodec With Dosing Guide App Versus Once-Daily Basal Insulin Analogues in Insulin-Naive Type 2 Diabetes (ONWARDS 5), https://doi.org/10.7326/M23-1288.